Abstract
Metal ions, particularly copper, zinc and iron, are implicated in several amyloidogenic neurodegenerative disorders. In the brain, as elsewhere in the body, metal ion excess or deficiency can potentially inhibit protein function, interfere with correct protein folding or, in the case of iron or copper, promote oxidative stress. The involvement of metal ions in neurodegenerative disorders has made them an emerging target for therapeutic interventions. One approach has been to chelate and sequester the ions and thus limit their potential to interfere with protein folding or render them unable to undergo redox processes. Newer approaches suggest that redistributing metal ions has therapeutic benefits, and recent studies indicate that alleviating cellular copper deficiency may be a plausible way to limit neurodegeneration. In this review we discuss the role of metals in amyloidogenic, neurodegenerative disorders and highlight some mechanisms and compounds used in various therapeutic approaches.
Keywords: Alzheimer's, chelator, copper, iron, neurodegeneration, Parkinson's, prion, redox, Creutzfeldt-Jakob disease, oxidative stress, neurodegenerative disorders, synucleinopathies, synuclein, zinc
Current Topics in Medicinal Chemistry
Title: Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Volume: 11 Issue: 5
Author(s): Alison C. Badrick and Christopher E. Jones
Affiliation:
Keywords: Alzheimer's, chelator, copper, iron, neurodegeneration, Parkinson's, prion, redox, Creutzfeldt-Jakob disease, oxidative stress, neurodegenerative disorders, synucleinopathies, synuclein, zinc
Abstract: Metal ions, particularly copper, zinc and iron, are implicated in several amyloidogenic neurodegenerative disorders. In the brain, as elsewhere in the body, metal ion excess or deficiency can potentially inhibit protein function, interfere with correct protein folding or, in the case of iron or copper, promote oxidative stress. The involvement of metal ions in neurodegenerative disorders has made them an emerging target for therapeutic interventions. One approach has been to chelate and sequester the ions and thus limit their potential to interfere with protein folding or render them unable to undergo redox processes. Newer approaches suggest that redistributing metal ions has therapeutic benefits, and recent studies indicate that alleviating cellular copper deficiency may be a plausible way to limit neurodegeneration. In this review we discuss the role of metals in amyloidogenic, neurodegenerative disorders and highlight some mechanisms and compounds used in various therapeutic approaches.
Export Options
About this article
Cite this article as:
C. Badrick Alison and E. Jones Christopher, Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease, Current Topics in Medicinal Chemistry 2011; 11 (5) . https://dx.doi.org/10.2174/156802611794785181
DOI https://dx.doi.org/10.2174/156802611794785181 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Etiopathogenesis and Treatment of Parkinsons Disease
Current Topics in Medicinal Chemistry PET Tracers for Serotonin Receptors and Their Applications
Central Nervous System Agents in Medicinal Chemistry A Review of Bioreactor Protocols for Human Neural Precursor Cell Expansion in Preparation for Clinical Trials
Current Stem Cell Research & Therapy Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Targeting Epigenetics in Nervous System Disease
CNS & Neurological Disorders - Drug Targets Signaling Mechanisms Underlying Aβ Toxicity: Potential Therapeutic Targets for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part B))
Current Pharmaceutical Design Novel Drug Delivery Systems for Releasing Growth Factors to the CNS: Focus on Alzheimer`s and Parkinson`s Diseases
Mini-Reviews in Medicinal Chemistry Application of Sulfamic Acid in Organic Synthesis-A Short Review
Current Organic Chemistry Prosodic Impairment in Dementia: Review of the Literature
Current Alzheimer Research Editorial [Hot Topic: New Developments in Therapy for Oxidative Stress-Related Diseases: Pathophysiological and Clinical Consequences (Executive Guest Editor: Victor M. Victor)]
Current Pharmaceutical Design Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson’s Disease
Current Aging Science Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis
Current Pharmaceutical Biotechnology A Novel Prescription for Alzheimer’s Disease: Targeting Hypercoagulable States
Current Neurovascular Research Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature
Current Topics in Medicinal Chemistry Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design